SCHEMBL4393216

SCHEMBL4393216

CN1CCN(CCCN(Cc2ccc(C(=O)Nc3ccccc3N)cc2)C(=O)Nc2ccc3c(c2)OCCO3)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.52
HDAC2 Q92769 2/20 0.52
ALDH1A1 P00352 5/20 0.45
RAB9A P51151 4/20 0.45
LMNA P02545 3/20 0.45
TP53 P04637 2/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
GLA P06280 1/20 0.44
TSHR P16473 2/20 0.44
NPC1 O15118 3/20 0.44
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
HDAC3 O15379 3/20 0.42
MAPT P10636 2/20 0.42
THRB P10828 1/20 0.42
NCOR2 Q9Y618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2474439 0.95 HDAC1 (0.53) HDAC1HDAC2ALDH1A1RAB9ALMNA
SCHEMBL2475826 0.94 HDAC1 (0.53) HDAC1HDAC2ALDH1A1RAB9ALMNA
SCHEMBL2506731 0.93 ALDH1A1 (0.54) HDAC1HDAC2ALDH1A1RAB9ALMNA
SCHEMBL2475910 0.92 HDAC1 (0.50) HDAC1HDAC2ALDH1A1RAB9ALMNA
SCHEMBL13646255 0.91 HDAC1 (0.51) HDAC1HDAC2ALDH1A1RAB9ALMNA
SCHEMBL3830885 0.91 HDAC1 (0.60) HDAC1HDAC2ALDH1A1RAB9ALMNA
SCHEMBL2386609 0.90 TSHR (0.43) HDAC1HDAC2ALDH1A1LMNATP53
SCHEMBL3835767 0.89 HDAC1 (0.56) HDAC1HDAC2ALDH1A1RAB9ALMNA
SCHEMBL3835176 0.88 ALDH1A1 (0.56) HDAC1HDAC2ALDH1A1RAB9ALMNA
SCHEMBL2473986 0.88 HDAC1 (0.59) HDAC1HDAC2ALDH1A1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HDAC1 200/4885HDAC2 129/4885ALDH1A1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.